Humacyte (HUMA) EBITDA Margin (2020 - 2026)
Humacyte (HUMA) posted quarterly EBITDA Margin of 5838.38% for Q1 2026, down 135096.0% year-over-year from N/an in Q1 2025, and up 11.58% quarter-over-quarter from 6603.21% in Q4 2025.
Humacyte (HUMA) EBITDA Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported EBITDA Margin for 4 consecutive years, with 5838.38% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 135096.0% year-over-year to 5838.38%; the TTM figure through Mar 2026 stood at 5647.52% (up 1582637.0% YoY), while the FY2025 annual figure was 5306.04%, changed N/A from the prior year.
- EBITDA Margin rose to 5838.38% in Q1 2026 per HUMA's latest filing, from 6603.21% in the prior quarter.
- Across five years, EBITDA Margin topped out at 3239.04% in Q3 2025 and bottomed at 9876.08% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | -6,649.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,649.26% |
| Mar 31, 2026 | -5,838.38% |
| Dec 31, 2025 | -6,603.21% |
| Sep 30, 2025 | -3,239.04% |
| Jun 30, 2025 | -9,876.08% |
| Mar 31, 2025 | -4,487.43% |
| Sep 30, 2021 | -8,524.07% |
| Sep 30, 2020 | -1,883.26% |